CBCharles BoucherMD, PhDSlidesetHIVViral Hepatitis and Liver DiseaseAndean Pacific Workshop on HIV & Hepatitis 2017New approaches for preventing transmission- Charles Boucher, MD, PhDView Slideset
APCdlTAna Paulina Celi de la TorreMDSlidesetHIVViral Hepatitis and Liver DiseaseAndean Pacific Workshop on HIV & Hepatitis 2017Difficult to reach populations in Latin America- Ana Paulina Celi de la Torre, MDView Slideset
MWMarcelo WolffMD, FACP, FIDSASlidesetHIVViral Hepatitis and Liver DiseaseAndean Pacific Workshop on HIV & Hepatitis 2017HIV in Latin America: 35 years later- Marcelo Wolff, MD, FACP, FIDSAView Slideset
AAAlejandro AfaniMDSlidesetHIVViral Hepatitis and Liver DiseaseAndean Pacific Workshop on HIV & Hepatitis 2017WHO Target 90-90-90 : Achievable for Latin America- Alejandro Afani, MDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016Evaluation of Pan Genotypic HCV NS3/4A Protease Inhibitor GS-9857 as the Object of Transporter and Cytochrome P450-Mediated Drug-Drug Interactions - Dr. Brian KirbyView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016A Clinically Meaningful Drug-Drug Interaction Observed Between ZepatierTM (Grazoprevir/Elbasvir) and Stribild® HIV Fixed-Dose Combination in Healthy Subjects - Dr. Hwa-Ping FengView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016Pharmacokinetics of Dolutegravir after Switching to Abacavir/Dolutegravir/Lamivudine from an Efavirenz Based Regimen: A PK Substudy from Striiving - Dr. Jeff de WetView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016Physiologically-based simulation of daclatasvir pharmacokinetics with antiretroviral inducers and inhibitors of cytochrome P450 and drug transporters - Dr. Timothy EleyView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016Pharmacokinetics of Darunavir, Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir and Ribavirin in Adults Infected with Hepatitis C Virus (HCV) Genotype (GT) 1 and Human Immunodeficiency Virus Type 1 (HIV-1) - Dr. Jennifer KingView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016MK-3682, a HCV NS5B Inhibitor with a Broad Spectrum of HCV Genotypic Activity, Demonstrates Potent Antiviral Activity in Genotypes -1,-2, and -3 HCV-Infected Patients - Dr. Nancy KimView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016Increased Tenofovir Diphosphate in Red Blood Cells, but Not Tenofovir in Plasma, with Sofosbuvir and Ribavirin - Dr. Christine MacBrayneView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy 2016Rifampin (RIF) Decreases Cabotegravir (CAB) Exposure following Oral Coadministration - Dr. Susan FordView Slideset
